McKesson Corporation vs MPLX LP — how do they compare? McKesson Corporation trades at $937.1 (market cap $108.46B), while MPLX LP trades at $56.35 (market cap $58.11B). The key difference: McKesson Corporation is the larger of the two by market cap, and MPLX LP pays the higher dividend (7.51%). Which is the better fit depends on your goals.
| MCK | MPLX | |
|---|---|---|
Market Cap | $108.46B | $58.11B |
Volume | 712,607 | 687,483 |
Sector | Health | Energy |
52-Week High | $995.69 | $60.51 |
52-Week Low | $725.17 | $47.80 |
Typical Hold Time | 74 Days | — |
Enterprise Value | $115.00B | $83.22B |
Dividend Yield | 0.4% | 7.51% |
Signals from Pluang's Aura AI — not financial advice
McKesson Corporation (MCK) trades at $938.84, up 3.13% with strong technical momentum and bullish analyst sentiment. The stock shows consistent earnings beats with Q2 2026 EPS of $9.93 exceeding expectations of $9.56. Recent news highlights the extension of McKesson's pharmaceutical distribution agreement with CVS Health through 2032, reinforcing long-term revenue visibility. Revenue growth remains robust, climbing from $264.0B in 2022 to $359.1B in 2025, though net margins are thin at 1.12%.
The outlook is positive with 81% analyst buy ratings and a $956.43 consensus price target. Key risks include margin pressure from drug pricing policies and high current liabilities of $61.60B. The stock's valuation at 24.95x P/E appears reasonable given earnings growth projections, but investors should monitor debt levels and regulatory developments in healthcare distribution.
MPLX trades at $56.12, down 1.63% with a bearish technical signal. The stock shows strong fundamentals with a 12.33 P/E ratio, 40.45% net income margin, and consistent dividend payments. Recent earnings show mixed results with Q4 2025 beating expectations but subsequent quarters missing targets. Analyst consensus remains strongly bullish with 19 buy ratings and a $63.80 price target, representing 13.7% upside potential from current levels.
The outlook remains positive given MPLX's resilient midstream business model with fee-based revenues insulating it from energy price volatility. Key risks include potential energy market downturns and execution challenges in the Permian Basin expansion. The company's strong cash flow generation supports its 8% dividend yield, making it attractive for income investors seeking energy exposure with reduced commodity price sensitivity.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →MPLX LP is a Master Limited Partnership (MLP) formed by Marathon Petroleum Corporation (MPC). It is a diversified, growth-oriented company primarily engaged in the gathering, processing, and transportation of natural gas and natural gas liquids (NGLs), as well as the transportation, storage, and distribution of crude oil and refined petroleum products. MPLX owns and operates a network of midstream energy infrastructure assets, providing essential services to the energy industry across the United States.
Read more on MPLX →